DZD9008

Phase 1Small molecule

DDizal Pharmaceuticals

DZD9008 is one of 62 small molecule programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 9

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Completed·DDizal Pharmaceuticals·Phase 1·NCT05926180·25 enrolled

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)

Recruiting·PPeking Union Medical College Hospital·N/A·NCT05559645·180 enrolled

Lymphoma1 trial

Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

Withdrawn·DDizal Pharmaceuticals·Phase 1/2·NCT04148742

Locally Advanced or Metastatic NSCLC1 trial

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Recruiting·DDizal Pharmaceuticals·Phase 2·NCT06276283·60 enrolled

Drug Interactions1 trial

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

Completed·DDizal Pharmaceuticals·Phase 1·NCT05418582·40 enrolled

Adult1 trial

Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

Completed·DDizal Pharmaceuticals·Phase 1·NCT04909242·78 enrolled

1 more indication

Hepatic Impairment1 trial

DZD9008 PK Study in Hepatic Impairment Subjects

Completed·DDizal Pharmaceuticals·Phase 1·NCT06084104·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for DZD9008. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DZD9008 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DZD9008. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dizal Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDizal Pharmaceuticals

DZD9008

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Lymphoma1 trial

Locally Advanced or Metastatic NSCLC1 trial

Drug Interactions1 trial

Adult1 trial

Hepatic Impairment1 trial

References

Drug Info

Quick Facts

Related News